A new trading day began on Tuesday, with Kymera Therapeutics Inc (NASDAQ: KYMR) stock price down -14.92% from the previous day of trading, before settling in for the closing price of $33.58. KYMR’s price has ranged from $19.44 to $53.27 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 233.20% over the past five years. Meanwhile, its annual earnings per share averaged -23.88%. With a float of $53.43 million, this company’s outstanding shares have now reached $64.89 million.
Let’s look at the performance matrix of the company that is accounted for 188 employees. In terms of profitability, gross margin is 84.34%, operating margin of -545.36%, and the pretax margin is -475.57%.
Kymera Therapeutics Inc (KYMR) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Kymera Therapeutics Inc is 17.74%, while institutional ownership is 95.39%. The most recent insider transaction that took place on Mar 03 ’25, was worth 68,239. In this transaction Chief Legal Officer of this company sold 2,241 shares at a rate of $30.45, taking the stock ownership to the 80,085 shares. Before that another transaction happened on Mar 03 ’25, when Company’s Chief Operating Officer sold 1,383 for $30.45, making the entire transaction worth $42,113. This insider now owns 67,800 shares in total.
Kymera Therapeutics Inc (KYMR) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -23.88% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.63% during the next five years compared to -26.36% drop over the previous five years of trading.
Kymera Therapeutics Inc (NASDAQ: KYMR) Trading Performance Indicators
Here are Kymera Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.53. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 39.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.97, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach -4.18 in one year’s time.
Technical Analysis of Kymera Therapeutics Inc (KYMR)
Kymera Therapeutics Inc (NASDAQ: KYMR) saw its 5-day average volume 0.76 million, a positive change from its year-to-date volume of 0.67 million. As of the previous 9 days, the stock’s Stochastic %D was 52.50%. Additionally, its Average True Range was 2.28.
During the past 100 days, Kymera Therapeutics Inc’s (KYMR) raw stochastic average was set at 33.54%, which indicates a significant decrease from 35.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 92.55% in the past 14 days, which was higher than the 74.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $30.20, while its 200-day Moving Average is $40.55. Nevertheless, the first resistance level for the watch stands at $31.95 in the near term. At $35.32, the stock is likely to face the second major resistance level. The third major resistance level sits at $37.13. If the price goes on to break the first support level at $26.77, it is likely to go to the next support level at $24.96. The third support level lies at $21.59 if the price breaches the second support level.
Kymera Therapeutics Inc (NASDAQ: KYMR) Key Stats
With a market capitalization of 1.86 billion, the company has a total of 65,117K Shares Outstanding. Currently, annual sales are 47,070 K while annual income is -223,860 K. The company’s previous quarter sales were 7,390 K while its latest quarter income was -70,750 K.
